Computational Amendment of Parenteral In Situ Forming Particulates’ Characteristics: Design of Experiment and PBPK Physiological Modeling
Abstract
Abstract: Lipid and/or polymer-based drug conjugates can potentially minimize side effects by increasing drug accumulation at target sites and thus augment patient compliance. Formulation factors can present a potent influence on the characteristics of the obtained systems. The selection of an appropriate solvent with satisfactory rheological properties, miscibility, and biocompatibility is essential to optimize drug release. This work presents a computational study of the effect of the basic formulation factors on the characteristics of the obtained in situ-forming particulates (IFPs) encapsulating a model drug using a 21.31 full factorial experimental design. The emulsion method was employed for the preparation of lipid and/or polymer-based IFPs. The IFP release profiles and parameters were computed. Additionally, a desirability study was carried out to choose the opti- mum formulation for further morphological examination, rheological study, and PBPK physiological modeling. Results revealed that the type of particulate forming agent (lipid/polymer) and the incor- poration of structure additives like Brij 52 and Eudragit RL can effectively augment the release profile as well as the burst of the drug. The optimized formulation exhibited a pseudoplastic rheological behavior and yielded uniformly spherical-shaped dense particulates with a PS of 573.92 ± 23.5 nm upon injection. Physiological modeling simulation revealed the pioneer pharmacokinetic properties of the optimized formulation compared to the observed data. These results assure the importance of controlling the formulation factors during drug development, the potentiality of the optimized IFPs for the intramuscular delivery of piroxicam, and the reliability of PBPK physiological modeling in predicting the biological performance of new formulations with effective cost management.
Â
References
References
Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol. 2011, 162, 1239–1249. [CrossRef] [PubMed]
Yun, Y.H.; Lee, B.K.; Park, K. Controlled Drug Delivery: Historical perspective for the next generation. J. Control. Release 2015, 219, 2–7. [CrossRef] [PubMed]
Tiwari, G.; Tiwari, R.; Sriwastawa, B.; Bhati, L.; Pandey, S.; Pandey, P.; Bannerjee, S.K. Drug delivery systems: An updated review.
Int. J. Pharm. Investig. 2012, 2, 2–11. [CrossRef]
Trenfield, S.J.; Basit, A.W. Modified Drug Release: Current Strategies and Novel Technologies for Oral Drug Delivery. In Nanotechnology for Oral Drug Delivery; Martins, J.P., Santos, H.A., Eds.; Academic Press: Cambridge, MA, USA, 2020; pp. 177–197, Chapter 6.
Rahnfeld, L.; Luciani, P. Injectable Lipid-Based Depot Formulations: Where Do We Stand? Pharmaceutics 2020, 12, 567. [CrossRef] [PubMed]
Patrick, M.G.; Vladimir, R.M. Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. J. Pharmacol. Exp. Ther. 2019, 370, 570.
Quarterman, J.C.; Geary, S.M.; Salem, A.K. Evolution of drug-eluting biomedical implants for sustained drug delivery. Eur. J. Pharm. Biopharm. 2021, 159, 21–35. [CrossRef]
Prasad, S.; Dangi, J.S. Targeting efficacy and anticancer activity of polymeric nanoparticles of SN-38 on colon cancer cell lines.
Futur. J. Pharm. Sci. 2023, 9, 1–9. [CrossRef]
Camargo, J.A.; Sapin, A.; Nouvel, C.; Daloz, D.; Leonard, M.; Bonneaux, F.; Six, J.L.; Maincent, P. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: Solvent selection based on physico-chemical characterization. Drug Dev. Ind. Pharm. 2013, 39, 146–155. [CrossRef]
S´miga-Matuszowicz, M.; Korytkowska-Wałach, A.; Nowak, B.; Pilawka, R.; Lesiak, M.; Sieron´, A.L. Poly(isosorbide succinate)-
based in situ forming implants as potential systems for local drug delivery: Preliminary studies. Mater. Sci. Eng. C 2018, 91, 311–317. [CrossRef]
Haider, M.; Elsayed, I.; Ahmed, I.S.; Fares, A.R. In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation. Pharmaceuticals 2021, 14, 66. [CrossRef]
Wang, X.; Burgess, D.J. Drug release from in situ forming implants and advances in release testing. Adv. Drug Deliv. Rev. 2021,
, 113912. [CrossRef]
Thakur, S.; Riyaz, B.; Patil, A.; Kaur, A.; Kapoor, B.; Mishra, V. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomed. Pharmacother. 2018, 106, 1011–1023. [CrossRef] [PubMed]
Derry, S.; Massey, T.; Moore, R.A.; McQuay, H.J. Topical NSAIDS for chronic musculoskeletal pain in adults. Cochrane Database Syst. Rev. 2008. [CrossRef]
Kasemiire, A.; Avohou, H.T.; De Bleye, C.; Sacre, P.-Y.; Dumont, E.; Hubert, P.; Ziemons, E. Design of experiments and design space approaches in the pharmaceutical bioprocess optimization. Eur. J. Pharm. Biopharm. 2021, 166, 144–154. [CrossRef] [PubMed]
Bowden, G.D.; Pichler, B.J.; Maurer, A. A Design of Experiments (DoE) Approach Accelerates the Optimization of Copper- Mediated 18F-Fluorination Reactions of Arylstannanes. Sci. Rep. 2019, 9, 11370. [CrossRef]
Fairman, K.; Li, M.; Ning, B.; Lumen, A. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges. Biochem. Pharmacol. 2021, 189, 114468. [CrossRef] [PubMed]
Zhao, P.; Rowland, M.; Huang, S.-M. Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions. Clin. Pharmacol. Ther. 2012, 92, 17–20. [CrossRef]
Zhao, P.; Zhang, L.; Grillo, J.A.; Liu, Q.; Bullock, J.M.; Moon, Y.J.; Song, P.; Brar, S.S.; Madabushi, R.; Wu, T.C.; et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review. Clin. Pharmacol. Ther. 2011, 89, 259–267. [CrossRef] [PubMed]
Deepika, D.; Kumar, V. The Role of “Physiologically Based Pharmacokinetic Model (PBPK)†New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment. Int. J. Environ. Res. Public Health 2023, 20, 3473. [CrossRef]
Alshawwa, S.Z.; Kassem, A.A.; Farid, R.M.; Mostafa, S.K.; Labib, G.S. Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence. Pharmaceutics 2022, 14, 883. [CrossRef] [PubMed]
Sager, J.E.; Yu, J.; Ragueneau-Majlessi, I.; Isoherranen, N. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab. Dispos. 2015, 43, 1823. [CrossRef]
Smits, A.; De Cock, P.; Vermeulen, A.; Allegaert, K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: How clinicians can contribute. Expert Opin. Drug Metab. Toxicol. 2019, 15, 25–34. [CrossRef]
Ammar, H.O.; Ibrahim, M.; Mahmoud, A.A.; Shamma, R.N.; El Hoffy, N.M. Non-ionic Surfactant Based In Situ Forming Vesicles as Controlled Parenteral Delivery Systems. AAPS PharmSciTech 2018, 19, 1001–1010. [CrossRef]
Antony, J. (Ed.) 1—Introduction to Industrial Experimentation. In Design of Experiments for Engineers and Scientists, 2nd ed.;
Elsevier: Oxford, UK, 2014; pp. 1–6.
Muralidharan, K.; Romero, M.; Wüthrich, K. Factorial Designs, Model Selection, and (Incorrect) Inference in Randomized Experiments. Rev. Econ. Stat. 2023, 1–44. [CrossRef]
Yu, M.; Yuan, W.; Li, D.; Schwendeman, A.; Schwendeman, S.P. Predicting drug release kinetics from nanocarriers inside dialysis bags. J. Control. Release 2019, 315, 23–30. [CrossRef] [PubMed]
Basak, S.C.; Kumar, K.S.; Ramalingam, M. Planejamento e caracterÃsticas de liberação de comprimidos de liberação controlada de cloridrato de metformina. Rev. Bras. Cienc. Farm. 2008, 44, 477–483. [CrossRef]
Onnainty, R.; Granero, G. Chitosan-based nanocomposites: Promising materials for drug delivery applications. In Biomedical Applications of Nanoparticles; Grumezescu, A.M., Ed.; William Andrew Publishing: New York, NY, USA, 2019; pp. 375–407, Chapter 14.
Buhr, E.; Senftleben, N.; Klein, T.; Bergmann, D.; Gnieser, D.; Frase, C.G.; Bosse, H. Characterization of nanoparticles by scanning electron microscopy in transmission mode. Meas. Sci. Technol. 2009, 20, 084025. [CrossRef]
Blasco-Martinez, A.B.; Mateo-Orobia, A.; Blasco-Alberto, J.; Pablo-Julvez, L. Rheological Behavior Patterns in Artificial Tears.
Optom. Vis. Sci. 2022, 99, 455–462. [CrossRef]
Thelen, K.; Coboeken, K.; Willmann, S.; Burghaus, R.; Dressman, J.B.; Lippert, J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions. J. Pharm. Sci. 2011, 100, 5324–5345. [CrossRef] [PubMed]
Ishizaki, T.; Nomura, T.; Abe, T. Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J. Pharmacokinet. Biopharm. 1979, 7, 369–381. [CrossRef]
Schmitt, W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol. In Vitro 2008, 22, 457–467. [CrossRef] [PubMed]
Hindmarsh, A.C.; Brown, P.N.; Grant, K.E.; Lee, S.L.; Serban, R.; Shumaker, D.E.; Woodward, C.S. SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers. ACM Trans. Math. Softw. 2005, 31, 363–396. [CrossRef]
Calvo, A.M.; Santos, G.M.; DionÃsio, T.J.; Marques, M.P.; Brozoski, D.T.; Lanchote, V.L.; Fernandes, M.H.R.; Faria, F.A.C.; Santos,
C.F. Quantification of piroxicam and 5′-hydroxypiroxicam in human plasma and saliva using liquid chromatography–tandem mass spectrometry following oral administration. J. Pharm. Biomed. Anal. 2016, 120, 212–220. [CrossRef]
Cho, C.; Kang, P.; Park, H.-J.; Ko, E.; Mu, C.Y.; Lee, Y.J.; Choi, C.-I.; Kim, H.S.; Jang, C.-G.; Bae, J.; et al. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Arch. Pharm. Res. 2022, 45, 352–366. [CrossRef]
Porras, M.; Solans, C.; González, C.; Gutiérrez, J. Properties of water-in-oil (W/O) nano-emulsions prepared by a low-energy emulsification method. Colloids Surf. A Physicochem. Eng. Asp. 2008, 324, 181–188. [CrossRef]
Saberi, A.H.; Fang, Y.; McClements, D.J. Fabrication of vitamin E-enriched nanoemulsions: Factors affecting particle size using spontaneous emulsification. J. Colloid Interface Sci. 2013, 391, 95–102. [CrossRef] [PubMed]
Kumar, N.; Goindi, S. Development and Optimization of Itraconazole-Loaded Solid Lipid Nanoparticles for Topical Adminis- tration Using High Shear Homogenization Process by Design of Experiments: In Vitro, Ex Vivo and In Vivo Evaluation. AAPS PharmSciTech 2021, 22, 248. [CrossRef]
Ammar, H.O.; Ibrahim, M.; Mahmoud, A.A.; Shamma, R.N.; El Hoffy, N.M. Polymer-Free Injectable In Situ Forming Nanovesicles as a New Platform for Controlled Parenteral Drug Delivery Systems. J. Pharm. Innov. 2022, 17, 391–398. [CrossRef]
Saharan, P.; Bahmani, K. Preparation, Optimization and In vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100. Pharm. Nanotechnol. 2019, 7, 72–85. [CrossRef]
Yacoub, A.S.; Ammar, H.O.; Ibrahim, M.; Mansour, S.M.; El Hoffy, N.M. Artificial intelligence-assisted development of in situ forming nanoparticles for arthritis therapy via intra-articular delivery. Drug Deliv. 2022, 29, 1423–1436. [CrossRef]
Galvao, J.; Davis, B.; Tilley, M.; Normando, E.; Duchen, M.R.; Cordeiro, M.F. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J. 2014, 28, 1317–1330. [CrossRef] [PubMed]
Sharma, M.; Sharma, R.; Jain, D.K. Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs. Scientifica 2016, 2016, 8525679. [CrossRef] [PubMed]